Skip to main content

Table 2 Difference in median OS and PFS between RCTs before and after 2012

From: Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation

  DOX arm Experimental arm
Before 2012 After 2012 p value Before 2012 After 2012 p value
Median OS, month (95% CI) 9.4 (8.4–12.0) 14.5 (13.2–27.3) 0.008 10.8 (9.0–11.7) 16.3 (13.3–38.9) 0.028
Median PFS, month (95% CI) 5.1 (2.7–9.3) 5.5 (4.6–6.1) 0.951 4.0 (2.0–6.8) 6.3 (2.8–8.3) 0.135
  1. Abbreviations: CI, confidence interval; DOX, doxorubicin; OS, overall survival; PFS, progression-free survival; RCT, randomized controlled trial